You are here: Home: BCU CME | 2005: Case 1: Select publications
 
     
 

SELECT PUBLICATIONS

Albain K et al. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-f luorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptorpositive breast cancer: Mature outcomes and new biologic correlates on Phase III Intergroup trial 0100 (SWOG-8814). Breast Cancer Res Treat 2004;88(Suppl 1):Abstract 37.

Allred D et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: Findings from NSABP Protocol B-24. Breast Cancer Res Treat 2002;30. No abstraqct available

Biganzoli L, Aapro M. Elderly breast cancer patients: Adjuvant chemotherapy and adjuvant endocrine therapy. Gynakol Geburtshilfliche Rundsch 2005;45(3):137-42. Abstract

Colleoni M et al. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol 2000;18(3):584-90. Abstract

Dowsett M, on behalf of the ATAC Trialists’ Group. Analysis of time to recurrence in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 2003;82(Suppl 1):Abstract 4.

Doyle JJ et al. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol 2005;23(34):8597-605. Abstract

Eaker S et al. Differences in Management of Older Women Inf luence Breast Cancer Survival: Results from a Population-Based Database in Sweden. PLoS Med 2006;3(3):e25;[Epub ahead of print]. Abstract

Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998;352(9132):930-42. Abstract

Fisher B et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320(8):479-84. Abstract

Goss PE et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97(17):1262-71. Abstract

Habel LA et al. Use of raloxifene among women with a history of breast cancer. Breast Cancer Res Treat.2005;[Epub ahead of print]. Abstract

Hind D et al. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev 2006;(1):CD004272. Abstract

Howell A et al; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract

Hussain SA et al. Endocrine therapy for early breast cancer. Expert Rev Anticancer Ther 2004;4(5):877-88. Abstract

Kaklamani VG, Gradishar WJ. Adjuvant therapy of breast cancer. Cancer Invest 2005;23(6):548-60. Abstract

Kaufmann M, Rody A. Long-term risk of breast cancer recurrence: The need for extended adjuvant therapy. J Cancer Res Clin Oncol 2005;131(8):487-94. Abstract

Kummel S et al. Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: Feasibility and tolerability in a subset of patients in a randomized trial. Crit Rev Oncol Hematol 2005;[Epub ahead of print]. Abstract

Lee JC et al. Postmastectomy radiotherapy reduces locoregional recurrence in elderly women with high-risk breast cancer. Clin Oncol (R Coll Radiol) 2005;17(8):623-9. Abstract

Leonard RC, Malinovszky KM. Chemotherapy for older women with early breast cancer. Clin Oncol (R Coll Radiol) 2005;17(4):244-8. Abstract

Morales L et al. Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting. Curr Opin Oncol 2005;17(6):559-65. Abstract

Mouridsen HT, Robert NJ. Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer. MedGenMed 2005;7(3):20. Abstract

Muss HB et al; Cancer and Leukemia Group B. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005;293(9):1073-81. Abstract

Olivotto IA et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005;23(12):2716-25. Abstract

Punglia RS et al. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: A decision analysis. J Clin Oncol 2005;23(22):5178-87. Abstract

Shamseddine A et al. Cisplatin and vinorelbine (PVn) for the treatment of advanced breast cancer: 10 years of experience. J Med Liban 2004;52(3):126-30. Abstract

Stemmler HJ et al. High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: A phase II study. Clin Oncol (R Coll Radiol) 2005;17(8):630-5. Abstract

Thürlimann B et al; Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353(26):2747-57. Abstract

Thürlimann B et al. Letrozole vs tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. BIG 1-98: A prospective randomized double-blind Phase III study. Breast 2005;14(Suppl 1):3;S4. No abstraqct available

Tobias JS. Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women. Int J Biochem Cell Biol 2004;36(11):2112-9. Abstract

Vrakking AM et al. Medical decision-making for seriously ill non-elderly and elderly patients. Health Policy 2005;75(1):40-8. Abstract

Wildiers H, Brain EG. Adjuvant chemotherapy in elderly patients with breast cancer: Where are we? Curr Opin Oncol 2005;17(6):566-72. Abstract

 

  
 
 
     
 
 


 
Editor’s Note:
Common questions about breast cancer from oncologists in community practice


Case 1: An active 79-year-old woman with a 7.5-centimeter, Grade II, ER/PR-positive, HER2-negative breast cancer with lymphovascular invasion and three positive nodes (from the practice of Dr Martha A Tracy)
- Select publications

Case 2: A 41-year-old premenopausal woman with an ER/PR-positive, HER2-positive infiltrating ductal carcinoma and six positive lymph nodes (from the practice of Dr Herbert I Rappaport)
- Select publications

Case 3: A 68-year-old woman with disease progression 10 years after presenting with hormone receptor-positive diffuse metastatic disease to the bone (from the practice of Dr Ghaleb A Saab)
- Select publications

Case 4: A 91-year-old woman with dementia who was diagnosed with Stage II, ER-positive, lymph node-negative breast cancer 15 years ago and now has diffuse bone metastases (from the practice of Dr Juliann M Smith)
- Select publications

Case 5: A 41-year-old surgically postmenopausal woman with a 3.5-centimeter, ER/PR-positive, HER2-positive tumor and two positive lymph nodes (from the practice of Dr Herbert I Rappaport)
- Select publications

Case 6: A 45-year-old premenopausal woman with a 0.7-cm, ER/PR-positive, HER2-positive tumor with 25 percent high-grade DCIS and an Oncotype DX™ recurrence score of 16 (from the practice of Dr Steven W Papish)
- Select publications

Case 7: A woman who presented in 1989 with an infiltrating lobular carcinoma and 21 positive nodes and was treated with adjuvant chemotherapy and tamoxifen and then develops metastatic disease and is treated over the next 11 years with a variety of chemotherapeutic and hormonal agents (from the practice of Dr Pamela Drullinsky)
- Select publications

Case 8: A 35-year-old woman with a 3.5-cm, ER/PR-positive, HER2-positive infiltrating ductal carcinoma and two positive sentinel lymph nodes treated on the nontrastuzumab- containing arm of the Intergroup N9831 trial (from the practice of Dr Pamela Drullinsky)
- Select publications
 
CME Information
Faculty Disclosures
Editor's Office